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Abstrak
Latar Belakang: Kanker kolorektal menempati urutan ketiga penyebab kanker di dunia, dengan prevalensi kanker 
rektum sebanyak 30% dari total kasus. Saat ini belum ada biomarker yang efektif untuk memprediksi respon 
pasien terhadap terapi yang diberikan. Beberapa penelitian menggunakan potensi miRNA sebagai biomarker 
untuk melihat respon terapi. Salah satunya yaitu MiR-124-3p berperan sebagai tumor supresor yang mengalami 
penurunan ekspresi pada berbagi jenis kanker. Tujuan dari penelitian ini adalah untuk meneliti ekspresi miR-124-
3p dari pasien kanker rektum yang menerima nCRT, dan menganalisis hubungannya dengan kelangsungan hidup 
pasien dan parameter klinis lainnya.
Metode: Penelitian ini melibatkan 15 orang pasien yang didiagnosis menderita kanker rektum lokal 
dan menjalani kemoradioterapi neoajuvan (radioterapi 45-50 Gy dengan fraksi 1,8-2 Gy selama 1-3 
bulan, dan kemoterapi 5-fluororacil secara oral). Sampel penelitian berupa darah intravena sebanyak 
5 ml diambil saat sebelum dan sesudah kemoradioterapi. Selanjutnya ekspresi miR-124-3p dianalisis 
menggunakan qRT-PCR dan dikalkulasi menggunakan metode Livak. 
Hasil: Terdapat hubungan signifikan antara peningkatan ekspresi miR-124-3p dengan sintasan hidup pasien 
(P=0,003; OR =30, 95% CI = 1,41 – 638,15), serta adanya peningkatan ekspresi miR-124-3p yang signifikan 
(P<0,041, fold change sebelum=1,14 ± 1,25; sesudah=2,4 ± 1,84) setelah dilakukan kemoradioterapi.
Kesimpulan: Hasil ini mengindikasikan bahwa miR-124-3p berpotensi menjadi biomarker untuk memprediksi sintasan 
hidup pasien kanker rektum yang menerima kemoradioterapi. (Health Science Journal of Indonesia 2019;10(2):90-5)
Kata kunci: kanker rektum, kemoradioterapi, miR-124-3p, sintasan hidup
Abstract 
Background: Colorectal cancer is the world’s third most prevalent cancer, which 30% of cases are rectal cancer. 
Today, the effective diagnostic marker to accurately predict clinical outcome patients response to therapy did not 
found yet. Several research studies have indicated that miRNA potential as a prognostic biomarker. MiR-124-
3p plays as tumor suppressor that significantly down-regulated in some cancer and could radiosensitize human 
colorectal cancer cells. The aim of the study is to investigate the expression of miR-124-3p from rectal cancer 
patient who receive nCRT, and analyze its association with patient survival and others clinical parameters.
Methods: This research involved 15 patients with histologically confirmed locally advanced rectal cancer 
(LARC) and received neoadjuvant chemotherapy/nCRT (radiotherapy 45-50 Gy with 1,8-2 Gy fractions over 1 
to 3 months and chemotherapy 5-fluorouracil was administered orally). Patient blood (5 ml) were collected from 
peripheral venous before and after neoadjuvant chemoradiotherapy. miR-124-3p expression was performed 
using qRT-PCR and calculate using Livak method. 
Results: In this study, we found that increasing of miR-124 was significantly associate with high survival 
of rectal cancer patient (P = 0,003; OR =30, 95% CI = 1,41 – 638,15). Average of miR-124-3p expression 
increase significantly after nCRT (P<0,041, fold change before=1,14 ± 1,25; after=2,4 ± 1,84). 
Conclusion: Our finding suggests that miR-124-3p expression in blood serum was potential as biomarkers to predict rectal 
cancer patient survival after neoajduvant chemoradiotherapy. (Health Science Journal of Indonesia 2019;10(2):90-5)
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Colorectal cancer is the world’s third most prevalent 
cancer and causing death due to cancer in the second 
rank. Rectal cancer occurs approximately 30% of all 
colorectal cancer cases and has higher reccurance 
and resistance to therapy than colon cancer.1,2 The 
standard treatment rectal cancer is called trimodality 
therapy, consist of neoadjuvant chemoradiotherapy 
(nCRT), then followed by a total mesorectal 
excision and chemotherapy. Organization of nCRT 
can essentially increment patient survival, however 
local reccurence is still common due to resistance. 
Approximately 40–60% of rectal cancer patients 
who treated with nCRT achieve improvement in 
the pathological reaction. Although about 40% of 
patients still recur and some of them were unable to 
survive.2,3 The overall 5-years survival rate for people 
with rectal cancer is 67%. However, colorectal cancer 
survival rates may differ based on several factors.3 
Today, many molecular mechanisms underlying 
sensitivity or resistance to chemoradiotherapy have 
been discovered and developed to accurately predict 
clinical result and response to rectal cancer treatment. 
MicroRNA (miRNA) is one of molecular factor 
that closely associates to tumor chemoradiotherapy 
sensitivity and appears great prospects of research 
and clinical application.
MiRNA is small endogenous non-coding RNA (19-
25 nucleotides) that regulates post-transcription 
gene expression by partly binds complementary 
sequences of its target messenger RNA (mRNA). 
This binding results in degradation and/or translation 
inhibition and leads to reduced protein expression. 
miRNA can function as an oncogenic (onco-miR) 
or tumor-suppressive (tumor-suppressor miR).4 
During the growth of cancer, miRNA expression 
is frequently deregulated in many types of cancer 
and cause abnormal level of expression that related 
with cancer clinicopathological characteristics. 
Therefore, the expression modifications of cancer-
associated miRNA emerge as promising diagnostic 
markers that correlate with cancer development of 
cancer, patient survival, sensitivity and resistance to 
therapy.5
MiR-124-3p or called miR-124 acts as a tumor 
suppressor that significantly down-regulated in many 
human malignant tumors including breast cancer, 
malignant glioma, gastric cancer, and colorectal 
cancer.6-9 Recent studies have shown that miR-124-
3p can radio sensitizes human colorectal cancer cells 
through PRRX1 targerting.9 MiR-124-3p may also be 
a prospective marker for gastric cancer and associated 
with poor prognosis in colorectal cancer. Increasing 
of miR-124-3p expression in colorectal cancer could 
inhibit colorectal cancer cells development.8,10
MiRNA can be secreted by cells and circulate in 
a stable phase in the human blood. Blood samples 
are easy to acquire and suitable for clinical use. 
Circulating miRNA are a new class of non-invasive 
biomarkers that show excellent stability under a 
multitude of physical and chemical circumtances.11 
The aim of this study is investigating the expression 
of miR-124-3p from blood serum in a rectal 
cancer patients who receive nCRT, and analyze its 
association with patient survival and other clinical 
parameters. Serum samples are much easier to obtain 
and simpler to access than cancer tissues. Serum 
based miRNAs can provide clues in rectal cancer 
therapy surveillance.
METHODS
Patients and sample collection
This Cohort study involved 15 patients with 
histologically confirmed locally advanced rectal 
cancer (LARC) with clinical TNM stage II and 
III, no history of previous malignancy based on 
MRI and histopathology examination. All patients 
received neoadjuvant chemoradiotherapy in Kariadi 
Hospital, Central Java, Indonesia, between 2017- 
early 2018. All patients received neoadjuvant 
chemoradiotherapy with 1,8-2 Gy fractions over 1 to 
3 months depending on radiotherapy 45-50 Gy and 
5-fluorouracil chemotherapy orally.
Patient blood (5 ml) were collected from peripheral 
venous, before and after neoadjuvant chemoradiation. 
By centrifugation at 3000 rpm for 15 minutes, serum 
was isolated from the blood. Serum samples were 
separated into 3 aliquots and stored at -80°C until 
further analysis. The characteristics of patients are 
shown in Table 1. This research was approved by 
the Medical Faculty of Diponegoro University and 
Kariadi Hospital Ethics Committee number 14/EC/
FK-RSDK/I/2017, then continued by the Medical, 
Public Health and Nursing Faculty Ethics Committee, 
Universitas Gadjah Mada (Ref : KE/FK/1008/
EC/2018), in accordance with the Declaration of 
Helsinki. All respondents acquired informed consent 
prior to enrollment in the research.
RNA isolation and cDNA synthesis
Total RNA was isolated from 200 μl of blood serum 
using miRCURYTM RNA Isolation Kit – Biofluids 
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(Qiagen), following the manufacture’s guidelines and 
specific application instruction. RNA concentration 
and purity were controlled by UV spectrophotometry 
using Nanodrop (NanoVue Plus, GE Healthcare, Life 
Science). Total RNA was eluted in RNAse-free water 
and stored at -800C until use. cDNA was synthesized 
using the reverse transcription reaction miRCURY 
LNA RT Kit (Exiqon) and performed using thermal 
cycler (Applied BiosystemsTM A24811) following the 
manufacture’s instructions and stored at -200C until use. 
Quantitative real-time PCR (qRT-PCR)
Analysis of qRT-PCR was performed using a SYBR-green-
containing PCR (miRCURY LNA SYBR Green PCR 
Kit, Qiagen) and samples were run on CFX96 TouchTM 
Real-Time PCR Detection System (Bio-Rad, USA) in 
a total volume 10 µl. U6 small non-coding RNA was 
used as a reference gene. The primer sequence for miR-
124-3p was 5’-UAAGGCACGCGGUGAAUGCC-3’ 
and U6 was 5′-CGCTTCGGCAGCACA TATACTA-3′ 
(miRCURY LNA miRNA PCR Assay, Qiagen). All 
these samples were standardized to reference gene and 
fold changes were calculated using the Livak’s method 
relative quantification (2-ΔΔCt).
Statistical methods
Categorical data are shown as the frequency counts 
and percentages, while continuous variables are 
shown as the mean plus or minus standard deviation. 
The association between miR-124-3p expression 
and patient’s characteristic was assessed using χ2 
test (Chi-square, Fisher’s exact test), while Odds 
Ratio (OR) equivalent to the 95% CI was used to 
evaluate the power of the associations. Significant 
differences in miR-124-3p expression before and 
after neoadjuvant chemoradiation were determined 
using Wilcoxon’s test. A statistically significant 
difference was regarded to show P-value < 0,05.
RESULTS
Patient clinicopathological characteristics
Table 1 shows the main clinicopathological charac-
teristics of 15 patients included in the study. Their median 
age was 46 years (range 26-65 years) and dominated by 
male. More than half of patients had well differentiated 
histopathology and had clinical stage III. Early CEA level 
average is 33,9 ng/mL, higher than the recommended 
normal level (5 ng/mL). Eleven patient from 2017 
until early 2018 who still alive until early 2019, were 
grouped as the patient who has high survival.
SD=standard deviation; n=amount of subject; T=tumor; N=node; 
TNM=Tumor size, Node status, Metastasis; CEA=carcino 
embryonic antigen; min=minimal; max=maximum
Relationship between miR-124-3p expression and 
patient clinicopathological characteristics
The relationship between miR-124-3p expression 
and clinicopathological characteristics is shown in 
Table 2. Increasing of miR-124-3p expression during 
nCRT were significantly associated with patient 
survival (P < 0,05; OR =30, 95% CI = 1,41-638,15). 
No significant relationship was observed between 
the miR-124-3p and sex, age, differentiation, early T 
stage, early N stage, early clinical TNM stage, down 
staging and early CEA level.
Average difference of miR-124-3p expression
Average difference of miR-124-3p expression and 
each patient are shown in Figure 1. MiR-124-3p 
expression increase significantly after nCRT (P<0,05, 
before=1,14 ± 1,25; after=2,4 ± 1,84; delta=1,26 
fold). MiR-124-3p expression increase in 11 patients 
(73%), which 10 patients could survive. During 
follow-up, 4 patients died of rectal cancer because 
of worse prognosis (patient no. 5, 6, 9, 13). Three of 
them have decrease miR-124-3p expression.





Female  5  (33)
Age (years)
Mean ± SD (min-max) 46,1 ± 12,1 (26-65)
Differentiation, n (%)
Well 11 (74)
Moderate  2  (13)
Poor  2  (13)
Early T Stages, n (%)




Early N Stages, n (%)
N0   2 (13)
N1   9 (60)
N2   4 (27)
Early Clinical TNM Stage, n (%)
II   2 (13)
III 13 (87)
Early CEA level (ng/mL)
Mean ± SD (min-max) 33,9 ± 68, 4 (0,04 – 200)
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OR (95% CI) PAfter Chemoradiation, n(%)
Increase Decrease
Sex   
   Male 7 (63,6) 3 (75)
0,58 (0,04 - 7,6) 0,593
   Female 4 (36,4) 1 (25)
Age
   < 50 7 (63,6) 2 (50)
1,75 (0,17 - 17,69) 0,538
   ≥ 50 4 (36,4) 2 (50)
Differentiation
   Well 8 (72,7) 2 (50)
2,67(0,25 - 28,44) 0,407
   Moderate - Poor 3 (27,3) 2 (50)
Early T Stages
   T1 - T2 3 (27,3) 0 (0)
1,5 (1 - 2,24) 0,363
   T3 - T4 8 (72,7) 4 (100)
Early N Stages
   N0 1 (9,1) 1 (25)
0,3 (0,14 - 6,38) 0,476
   N1 - N2 10 (90,9) 3 (75)
Early Clinical TNM Stage
   II 1 (9,1) 1 (25)
0,3 (0,01 - 6,38) 0,476
   III 10 (90,9) 3 (75)
Down staging
   Yes 9 (81,8) 4 (100)
0,69 (0,48 - 0,99) 0,542
   No 2 (18,2) 0 (0)
Early CEA level
   Normal (≤ 5 ng/mL) 3 (42,9) 1 (33,3)
1,5 (0,09 - 25,39) 0,667
   Elevated (> 5 ng/mL) 4 (57,1) 2 (66,7)
Survival
   Survive 10 (90,9) 1 (25)
30 (1,41 - 638,15) 0,033*
   Died 1 (9,1) 3 (75)
TNM=Tumor size, Node status, Metastasis; CEA=carcino embryonic antigen
Chi-square test (Fisher’s exact test) *P-value significant < 0,05
Wilcoxon’s test, P significant < 0,05
Figure 1. Difference of average miR-124-3p expression before and after nCRT (left); difference of miR-124-3p expression 
in each patients (right).
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DISCUSSION
In rectal cancer clinical management, a recurrence and 
resistance after therapy is a challenging obstacle. Cancer 
generally more heterogeneous during carcinogenesis 
influenced by complex mechanism and affect to varies 
therapy result. Independent variables in clinical practice, 
such as pathological subtype, histological type, clinical 
stage, lymph node status and interval, may affect the 
prognosis of LARC patients receiving chemoradiotherapy. 
Some molecular factors can also influence the prognosis 
and sensitivity LARC patients to chemoradiotherapy due 
to genetic, transcriptomic, epigenetic and/or phenotypic 
changes.12 This study focuses mainly on epigenetic, 
particularly microRNA.
Chemoradiotherapy resistance is an important factor 
that influences the prognosis of LARC. Therefore, 
predictive biomarkers capable of predicting 
sensitivity to chemoradiotherapy urgently need to 
help identify patients who would actually benefit 
from chemoradiotherapy. Chemoradio-resistance 
is a complicated process, involving cancer stem 
cell or tumor-initiating cells (TICs), angiogenesis 
which promotes by tumor-associated macrophages 
(TAMs), overexpression of DNA repair protein and 
autophagy.13-15 Some earlier study has shown that 
miRNAs are associated with tumor cell chemoradio-
sensitivity. MiRNA overexpression in tumor cells may 
increase or decrease chemoradio-sensitivity. Some 
miRNA expression has been down-regulated in resistant 
patients, but after up-regulation or administration, it 
may improve the impact of chemoradiotherapy.16,17 
In this research, we examine the difference of miR-124-
3p expression in the LARC patient serum before and 
after neoadjuvant chemoradiotherapy, and focusing on 
its relationship with patient survival for 1-2 years after 
treatment. Notably, more than half of patients who can 
survive after neoadjuvant chemoradiotherapy have 
an increase miR-124-3p expression and both variable 
significantly associated (P < 0,05; OR =30, 95% CI 
= 1,41 – 638,15). Although interesting, the limitation 
of this study obtained in small sample size of patients 
with cancer treated, so we suppose that a more precise 
result will be determined by a massive measurement of 
subjects for the next study.
In earlier study, some radiation resistance model 
of cell line was developed and miRNA-mediated 
molecular mechanism was investigated. MiR-124-
3p in the radiation-resistant cell line was found to 
be considerably down-regulated. Down-regulation 
of miR-124-3p is linked with metastasis and poor 
prognosis in colorectal cancer.18 Whereas miR-124-3p 
over-expression has been able to sensitize radiation-
resistant cells by reducing the fraction of cell survival 
and viability19,20. It can be used as independent 
prognostic factor in colorectal cancer patient.21
MiR-124-3p has been involved as modulator of 
colorectal cancer carcinogenesis in many past 
studies. Some targets of miR-124-3p were identified 
in the regulation of colorectal cancer. MiR-124-
3p regulates colorectal cancer growth by targeting 
PKM (pyruvate kinase muscle) gene that plays a role 
inhibit glycolysis rate in Warburg effect and also 
targets PRPS1 and RPIA gene that reduces pentose 
phosphate pathway and proliferation.22,23 MiR-124-
3p enhance radiotherapy sensitivity by targeting 
PRRX1, which act as epithelial-mesenchymal 
transition (EMT) inducer and stemness regulator 
and directly targets DNA methyltransferase 3B and 
DNMT1 in a colorectal cancer cell. miR-124-3p 
have multiple effects and targets in the development 
of colorectal cancer, become very potential for 
therapeutic target in the future.9,24
In conclusion, we identified that the average of 
miR-124-3p expression in rectal cancer patient with 
good prognosis was increased after neoadjuvant 
chemoradiotherapy and associate with high 
survival rate of patient. MiR-124-3p was found 
high-abundance and easy to identify in serum. Our 
study showed that miR-124-3p expression in blood 
serum was potential as biomarkers to predict the 
survival of rectal cancer patients after neoadjuvant 
chemoradiotherapy.
Acknowledgment
We gratefully thank to Head of Oncology and 
Radiology Department of Kariadi Hospital, Tirta 
Wardhana and Mr. A. Hamim Sadewa for support 
on this writing. This research study was supported 
by Community Fund Grant from Medical Faculty 
of Universitas Gadjah Mada (Post Graduate Scheme 
2018) and Research Scholarship Fund from Ministry 
of Health. Both supporting sources had no involvement 
nor influence on the content of this manuscript.
REFERENCES
1. World Health Organization [Internet]. Cancer.  [cited 
2019 March 10]. Available from: URL:https://www.
who.int/news-room/factsheets/detail/ cancer.
2. Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger 
W, Hess C. Preoperative versus postoperative 
Vol. 10, No. 2, December 2019 MiR-124-3p expression in rectal cancer patient 95
chemoradiotherapy for locally advanced rectal 
cancer: results of the German CAO/ARO/AIO-94 
randomized phase III trial after a median follow-up 
of 11 years. J Clin Oncol. 2012;30(16):1926–33. 
3. Conde-Muino R, Cuadros M, Zambudio N, Segura-
Jimenez I, Cano C, Palma P. Predictive biomarkers 
to chemoradiation in locally advanced rectal cancer. 
BioMed Res Int. 2015. Article ID 921435 1-10.
4. Ha M, Kim VN. Regulation of microRNA 
biogenesis. Nat Rev Mol Cell Bio. 2014;15(8):509 – 24.
5. Lin S, Gregory RI. MicroRNA biogenesis pathways 
in cancer. Nat Rev Cancer. 2015;15(6):321-33.
6. Wang Y, Chen L, Wu Z, Wang M, Jin F, Wang N, 
et al. miR-124-3p functions as a tumor suppressor 
in breast cancer by targeting CBL. BMC Cancer. 
2016;16(826):1-9. 
7. Luo L, Chi H, Ling J. Mir-124-3p suppresses glioma 
aggressiveness via targeting of Fra-2. Pathol Research 
Prac. 2018;214(11):1825-34. 
8. Liu F, Hu H, Zhao J, Zhang Z, Ai X, Tang L, et al. miR-
124-3p acts as a potential marker and suppresses tumor 
growth in gastric cancer. Biomed Rep. 2018;9(2):147-55.
9. Zhang Y, Zheng L, Huang J, Gao F,Lin X, He L, et al. 
Mir-124 radiosensitizes human colorectal cancer cells 
by targeting PRRX1. Plos One. 2014;9 (4):1-9. 
10. Sun Y, Zhao X, Zhou Y, Hu Y. MiR-124, miR-137 
and miR-340 regulate colorectal cancer growth 
via inhibition of the Warburg effect. Oncol Rep. 
2012;28(4):1346 –52. 
11. Kai K, Dittmar RL, Sen S. Secretory microRNA 
as biomarkers of cancer. Semin Cell Dev Biol. 
2018;78:22-36.
12. Dagogo-Jack I, Shaw AT. Tumor heterogeneity and 
resistance to cancer therapies. Nat Rev Clin Oncol. 
2018;15(2):81-94.
13. Chiang C, Fu SY, Wang S, Yu C, Chen F, Lin C, et al. 
Irradiation promotes an M2 macrophage phenotype in 
tumor hypoxia. Front Oncol. 2012;2(89):1-12. 
14. Torgovnick A, Scumacher B. DNA repair mechanism 
in cancer development and therapy. Front genet. 
2015;6(157):1-15.
15. Yao WY, Kang KA, Piao MJ, Ryu YS, Fernando PMDJ, 
Oh MC, et al. Reduced autophagy in 5-fluororacil resistant 
colon cancer cells. Biomol  Ther. 2017;25(3):315-20
16. Templin T. Radiation-induced micro-RNA expression 
changes in peripheral blood cells of radiotherapy patients. 
Int J Radiat Oncol. Biol Phys 2011;80(2):549–57  
17. Ondracek J. Global microRNA expression profiling 
identifies unique microRNA pattern of radioresistant glio-
blastoma cells. Anticancer Res. 2017;37(3):1099–104  
18. Jinushi T, Shibayama Y, Kinoshita I, Oizumi S, Jinushi M, 
Aota T, et al. Low expression levels of microRNA-124-
5p correlated with poor prognosis in colorectal cancer via 
targeting of SMC4. Cancer Med. 2014;3(6):1544–52
19. Hao C, Xu X, Ma J, Dai B, Liu L, Ma Y. Micro-
RNA regulates the radiosensitivity of non-small cell 
lung cancer cells by targeting TXNRD1. Oncol Lett. 
2017;13(4):2071-8. 
20. Zhang YH, Wang QQ, Li H, Ye T, Gao F, Liu YC. miR-
124 radiosensitize human esophageal cancer cell TE-1 by 
targeting CDK4. Genet Mol Res. 2016;15(2):1-10.
21. Wang MJ, Li Y, Wang R, Wang C, Yu YY, Yang L, et al. 
Down regulation of microRNA-124 is an independent 
prognostic factor in patients with colorectal cancer. Int J 
Colorectal Dis. 2013;(28)2:183-9.
22. Sun Y, Zhao X, Zhou Y, Hu Y. miR-124, miR-137 and 
miR-340 regulate colorectal cancer growth via inhibition 
of the Warburg effect. Oncol Rep. 2012;28(4):1346-52. 
23. Qiu Z, Guo W, Wang Q, Chen Z, Huang S, Zhao F, et 
al. MicroRNA-124 reduces pentose phosphate pathway 
and proliferation by targeting PRPS1 and RPIA mRNAs 
in human colorectal cancer cells. Gastroenterology. 
2015;149(6):1587-98.
24. Chen Z, Liu S, Tian L, Wu M, Ai F, Tang W, et al. miR-
124 and miR-506 inhibit colorectal cancer progression 
by targeting DNMT3B and DNMT1. Oncotarget. 
2015;6(35):38139–50. 
